

**VAXOMAX (PTY) LIMITED**  
**Abridged Unaudited Financial Statements**  
**for the financial year ended 28 February 2025**

**VAXOMAX (PTY) LIMITED**  
**Abridged Unaudited Financial Statements**  
**for the financial year ended 28 February 2025**

---

**Contents**

|                                   |   |
|-----------------------------------|---|
| Company Information               | 2 |
| Profit and Loss Account           | 3 |
| Balance Sheet                     | 4 |
| Notes to the Financial Statements | 5 |

**VAXOMAX (PTY) LIMITED**

**COMPANY INFORMATION**

**for the financial year ended 28 February 2025**

---

**DIRECTORS**

Catherine Shields  
Rosanne Shields  
Tiernan Shields

**SECRETARY**

Roolt Business Services Limited

**REGISTERED OFFICE**

Ground Floor  
71 Lower Baggot Street  
Dublin  
D02 P593  
Ireland

**COMPANY NUMBER**

666699

**CHARTERED ACCOUNTANTS**

Lizdan Business Services Limited t/a Kinore  
Ground Floor  
71 Baggot Street Lower  
Dublin  
D02 P593  
Ireland

**BANKERS**

AIB  
Pearse Street  
Ballina  
Co. Mayo

**VAXOMAX (PTY) LIMITED**  
**PROFIT AND LOSS ACCOUNT**  
**for the financial year ended 28 February 2025**

---

|   | <b>2025</b>            | <b>2024</b>            |
|---|------------------------|------------------------|
|   | <b>€</b>               | <b>€</b>               |
| Depreciation and other amounts written off assets | (9,791)                | (800)                  |
| Other charges                                     | (16,094)               | (28,217)               |
| <b>Loss for the financial year</b>                | <b><u>(25,885)</u></b> | <b><u>(29,017)</u></b> |

VAXOMAX (PTY) LIMITED

BALANCE SHEET

As at 28 February 2025

|  | 2025             | 2024             |
|--|------------------|------------------|
|  | €                | €                |
| Fixed assets                                   | 329,232          | 369,028          |
| Current assets                                 | 2,220            | 988              |
| Prepayments and accrued income                 | 1,592            | -                |
| Creditors: amounts falling due within one year | (426,261)        | (438,194)        |
| <b>Net current liabilities</b>                 | <b>(422,449)</b> | <b>(437,206)</b> |
| <b>Total assets less current liabilities</b>   | <b>(93,217)</b>  | <b>(68,178)</b>  |
| Accruals and deferred income                   | (1,732)          | (886)            |
| <b>Net liabilities</b>                         | <b>(94,949)</b>  | <b>(69,064)</b>  |
| <b>Capital and reserves</b>                    | <b>(94,949)</b>  | <b>(69,064)</b>  |

We, as directors of Vaxomax (PTY) Limited, state that:

- The Company is availing itself of the exemption provided for by Chapter 15 of Part 6 of the Companies Act 2014,
- The Company is availing itself of the exemption on the grounds that the conditions specified in s.358 are satisfied,
- The shareholders of the Company have not served a notice on the Company under s.334(1) in accordance with s.334(2),
- We acknowledge the Company's obligations under the Companies Act 2014 and to keep adequate accounting records and prepare financial statements which give a true and fair view of the assets, liabilities and financial position of the Company at the end of its financial year and of its profit or loss for such a year and to otherwise comply with the provisions of Companies Act 2014 relating to financial statements so far as they are applicable to the Company,
- The Company has relied on the specified exemption contained in s.352 Companies Act 2014 and has done so on the grounds that the Company is entitled to the benefit of that exemption as a small company and the abridged financial statements have been properly prepared in accordance with s.353 Companies Act 2014.

These financial statements have been prepared in accordance with the micro companies regime.

The financial statements of Vaxomax (PTY) Limited (registered number: 666699) were approved and authorised for issue by the Board of Directors on 06 January 2026 and were signed on its behalf by:



Tiernan Shields  
Director



Rosanne Shields  
Director

**VAXOMAX (PTY) LIMITED**  
**NOTES TO THE ABRIDGED FINANCIAL STATEMENTS**  
**for the financial year ended 28 February 2025**

---

**1. Accounting policies**

The principal accounting policies are summarised below. They have all been applied consistently throughout the financial year and to the preceding financial year, unless otherwise stated.

**General information and basis of accounting**

Vaxomax (PTY) Limited (registered number 666699) (the Company) is a private company, limited by shares, registered in Ireland under the Companies Act 2014. The address of the registered office is Ground Floor, 71 Lower Baggot Street, Dublin, D02 P593, Ireland.

The financial statements have been prepared under the historical cost convention and in accordance with FRS 105 'The Financial Reporting Standard applicable to the Micro-entities Regime'.

The functional currency of Vaxomax (PTY) Limited is considered to be EUR because that is the currency of the primary economic environment in which the Company operates.

**Going concern**

The directors have assessed the Balance Sheet and likely future cash flows at the date of approving these financial statements. The directors note that the business has net liabilities of €94,949. The Company is supported through loans from the Parent Company. The directors have a reasonable expectation that the Company has adequate resources to continue in operational existence and to meet its financial obligations as they fall due for at least 12 months from the date of signing these financial statements. Accordingly, they continue to adopt the going concern basis in preparing the financial statements.

**Turnover**

Turnover comprises the invoice value services supplied by the company, exclusive of trade discounts and value added tax.

Turnover from the provision of services is recognised when the amount of revenue can be measured reliably; it is probable that the associated economic benefits will flow to the entity; and the costs incurred or to be incurred in respect of the transactions can be measured reliably.

VAXOMAX (PTY) LIMITED

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS (continued)  
for the financial year ended 28 February 2025

---

**Taxation**

**Current tax**

Current tax, including Irish corporation tax and foreign tax, is provided at amounts expected to be paid (or recovered) using the tax rates and laws that have been enacted or substantively enacted by the Balance Sheet date.

A provision is recognised for those matters for which the tax determination is uncertain but it is considered probable that there will be a future outflow of funds to a tax authority. The provisions are measured at the best estimate of the amount expected to become payable. The assessment is based on the judgement of tax professionals within the Company supported by previous experience in respect of such activities and in certain cases based on specialist independent tax advice.

Where items recognised in other comprehensive income or equity are chargeable to or deductible for tax purposes, the resulting current or deferred tax expense or income is recognised in the same component of comprehensive income or equity as the transaction or other event that resulted in the tax expense or income.

Current tax assets and liabilities are offset only when there is a legally enforceable right to set off the amounts and the Company intends either to settle on a net basis or to realise the asset and settle the liability simultaneously.

**Tangible fixed assets**

Tangible fixed assets are stated at cost or valuation, net of depreciation and any provision for impairment. Depreciation is provided on all tangible fixed assets, other than investment property and freehold land, at rates calculated to write off the cost or valuation, less estimated residual value, of each asset on a straight-line or reducing balance basis over its expected useful life, as follows:

|                     |                        |
|---------------------|------------------------|
| Land and buildings  | not depreciated        |
| Investment property | 50 years straight line |
| Vehicles            | 5 years straight line  |

Residual value represents the estimated amount which would currently be obtained from disposal of an asset, after deducting estimated costs of disposal, if the asset were already of the age and in the condition expected at the end of its useful life.

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

**Impairment of assets**

Assets, other than those measured at fair value, are assessed for indicators of impairment at each Balance Sheet date. If there is objective evidence of impairment, an impairment loss is recognised in the Profit and Loss Account as described below.

**VAXOMAX (PTY) LIMITED**  
**NOTES TO THE ABRIDGED FINANCIAL STATEMENTS (continued)**  
**for the financial year ended 28 February 2025**

---

**Investment property**

Investment property is property (land or buildings) held to earn rentals or for capital appreciation, or both. Investment property is initially measured at cost, which includes purchase price and directly attributable costs.

Subsequent to initial recognition, investment property is measured at cost less accumulated depreciation and impairment losses.

**Trade and other debtors**

Trade and other debtors are measured initially at transaction price and thereafter stated at amortised cost using the effective interest method less impairment losses for bad and doubtful debts except where the effect of discounting would be immaterial. In such cases the receivables are stated at cost less impairment losses for bad and doubtful debts.

**Cash and cash equivalents**

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in creditors: amounts falling due within one year.

**Trade and other creditors**

Trade and other creditors are measured initially at transaction price and thereafter stated at amortised cost using the effective interest rate method unless the effect of discounting would be immaterial, in which case they are stated at cost.

**Ordinary share capital**

The ordinary share capital of the Company is presented as equity.

**2. Appropriation of profit and loss**

|                                 | <b>Profit and loss<br/>account</b> |
|---------------------------------|------------------------------------|
|                                 | €                                  |
| <b>At 01 March 2023</b>         | <b>(40,148)</b>                    |
| Loss for the financial year     | (29,017)                           |
| <b>Total comprehensive loss</b> | <b>(29,017)</b>                    |
| Rounding                        | 1                                  |
| <b>At 29 February 2024</b>      | <b>(69,164)</b>                    |

**VAXOMAX (PTY) LIMITED**  
**NOTES TO THE ABRIDGED FINANCIAL STATEMENTS (continued)**  
**for the financial year ended 28 February 2025**

---

|                                 |                 |
|---------------------------------|-----------------|
| <b>At 01 March 2024</b>         | <b>(69,164)</b> |
| Loss for the financial year     | (25,885)        |
| <b>Total comprehensive loss</b> | <b>(25,885)</b> |
| <b>At 28 February 2025</b>      | <b>(95,049)</b> |